Welcome to our dedicated page for Viveon Health Acquisition news (Ticker: VHAQU), a resource for investors and traders seeking the latest updates and insights on Viveon Health Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viveon Health Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viveon Health Acquisition's position in the market.
Viveon Health Acquisition Corp. (VHAQ) has made significant progress towards its business combination with Suneva Medical, Inc.. A registration statement on Form S-4 was filed with the SEC on
Viveon Health Acquisition Corp. (NYSE: VHAQU) announced on May 24, 2022, that it received a notice from the NYSE regarding non-compliance with filing requirements due to its inability to file the Quarterly Report on Form 10-Q for the period ended March 31, 2022. The NYSE’s notice allows for up to 12 months to cure the deficiency, with an initial six months automatically granted. The company is working to complete its financial disclosures and expects to file the Form 10-Q by June 10, 2022, though this timeline is uncertain.
Suneva Medical achieved a significant milestone by distributing over 1 million syringes of Bellafill in 2021, a five-year FDA-approved dermal filler. Bellafill, designed for correcting nasolabial folds and acne scars, shows a low adverse event rate of 0.11% in extensive clinical studies. CEO Pat Altavilla highlighted the growing patient demand for longer-lasting fillers like Bellafill, addressing 'filler fatigue.' An announced merger with Viveon Health Acquisition Corp. (NYSE: VHAQ) is set to bolster growth and market presence.
